Skip to content

Role of Endovascular Embolization in Gene Expression of Intracranial Vascular Malformations

Role of Endovascular Embolization in Gene Expression of Intracranial Vascular Malformations

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098045
Enrollment
Unknown
Registered
2025-02-28
Start date
2025-02-28
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Vascular Malformations

Interventions

Post-Embolization Resection Group:Null
Immediate Post-Embolization Resection Group:Null
Direct Resection Group:Null

Sponsors

General Hospital of Northern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: a) Imaging-assured intracranial vascular malformation; b) Age between 18 and 75 years; c) Diagnosed with primary intracranial vascular malformation.

Exclusion criteria

Exclusion criteria: a) Age less than 18 years old or greater than 75 years old; b) Not primary intracranial vascular malformation; c) Pregnancy, lactating patients; d) Combined with severe cardiopulmonary insufficiency, liver and kidney insufficiency or severe systemic complications; e) Combined with moyamoya disease, neurofibromatosis, central nervous system vasculitis, radiation - induced vascular injury and other serious cerebrovascular diseases, or systemic diseases such as systemic lupus erythematosus, Behcet's disease, etc., which may interfere with the study results; f) Incomplete clinical data, unable to clearly determine key information such as recanalization of lesions, recurrence or nature of lesions before surgery; g) The specimen storage conditions do not meet the experimental requirements, resulting in substandard sample quality; h) Other patients whom the clinician considers unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Histological analysis: Hematoxylin and Eosin (H&E) stains;Histological analysis: Masson's trichrome stains;Protein analysis: Western Blot (WB);Omics analysis: Transcriptomics;

Countries

China

Contacts

Public ContactLiang Guobiao

General Hospital of Northern Theater Command

liangguobiao6708@163.com+86 138 9886 6708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026